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Abstract: Selenoesters and the selenium isostere of phthalic anhydride are bioactive selenium 
compounds with a reported promising activity in cancer, both due to their cytotoxicity and capacity 
to reverse multidrug resistance. Herein we evaluate the antiviral, the biofilm inhibitory, the 
antibacterial and the antifungal activities of these compounds. The selenoanhydride and 7 out of 
the 10 selenoesters were especially potent antiviral agents in Vero cells infected with herpes simplex 
virus-2 (HSV-2). In addition, the tested selenium derivatives showed interesting antibiofilm activity 
against Staphylococcus aureus and Salmonella enterica serovar Typhimurium, as well as a moderate 
antifungal activity in resistant strains of Candida spp. They were inactive against anaerobes, which 
may indicate that the mechanism of action of these derivatives depends on the presence of oxygen. 
The capacity to inhibit the bacterial biofilm can be of particular interest in the treatment of 
nosocomial infections and in the coating of surfaces of prostheses. Finally, the potent antiviral 
activity observed converts these selenium derivatives into promising antiviral agents with potential 
medical applications. 
Keywords: selenoesters; selenoanhydrides; antivirals; biofilm inhibitors; antibacterials; antifungals; 
HSV-2; Staphylococcus aureus; Salmonella Typhimurium; Candida spp 
 
1. Introduction 
Oxidative stress plays an important role in viral infection and viral pathogenesis. The majority 
of viruses causes an increase in the levels of reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) in the infected cells [1–3]. This increase can be caused by the immunological response 
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against the infection (as the release of pro-oxidant cytokines or the recruitment and activation of 
phagocytic cells) [1] or by the intrinsic capacity of viral components to generate ROS [1–5]. As an 
example, RNA viruses can generate chronic oxidative stress [4], and certain viruses can even exploit 
many redox-regulated intracellular signaling pathways, to replicate inside the host cells [5]. Thus, 
compounds with antioxidant activity can prevent the viral action or at least can attenuate the 
symptoms [2,5]. 
In this context, selenium (Se) and the Se-containing compounds are known antioxidants [6–8]. 
This chalcogen is the crucial element that makes possible the antioxidant activity of the glutathione 
peroxidase, the enzyme that enables the deactivation of the hydrogen peroxides [7,8]. In line with 
this, patients with persistent viral infections such as HIV-1 (Human Immunodeficiency Virus) 
infection, usually show high oxidative stress levels. Thus, the reduction of this chronic oxidative 
stress through different antioxidants as Se can reduce the virulence of these viral infections [7,8]. In 
addition, the Se deficiency, combined with the infection with coxsackievirus, leads to the 
development of the Keshan disease, a severe congestive cardiomyopathy [8]. 
Thus, the broad relationship between Se deficiency and viral infections is well-known [7,8]. The 
antiviral properties of certain selenocompounds have also been described [9–18]. For instance, 
ebselen prevents the replication of the hepatitis C virus through the inhibition of a viral helicase [9], 
and diphenyl diselenide exerts antiviral activity against Herpes Simplex Virus-2 (HSV-2) [10]. In 
addition, benzoisoselenazol-3-(2H)-ones showed a more potent antiviral activity than their non-Se 
analogues against Herpes Simplex Virus-1 (HSV-1), Encephalomyocarditis Virus (ECMV) and 
Vesicular Stomatitis Virus (VSV) [11]; sodium selenite blocks the replication of hepatitis B virus in 
liver cancer cell lines [12], and biogenic Se nanoparticles (SeNPs) obtained from actinobacterial strains 
showed a potent antiviral activity against dengue virus [13]. Moreover, SeNPs functionalized with 
antiviral agents (ribavirin, amantadine and oseltamivir) reduced the effects of the infection by H1N1 
influenza virus [14–16]. Finally, the Se-analogues or derivatives of antiviral drugs as selenoacyclovir, 
selenogancyclovir and selenazole-substituted ritonavir exerted a potent and moderate activity 
against HSV-1 [17], Human Cytomegalovirus (HCMV) [17] and HIV [18], respectively. 
Among bacterial pathogens, Staphylococcus aureus is a globally important Gram-positive 
pathogen that frequently causes nosocomial and community-acquired infections. This bacterium is 
capable of biofilm formation; namely, it is able to attach to the surface of medical devices 
(pacemakers, implants, catheters) and can even colonize host tissue in case of chronic infection [19–
21]. Salmonella enterica serovar Typhimurium is a human foodborne pathogen that causes acute 
inflammatory diarrhea, which can generate a systemic disease mostly in immunocompromised 
patients [22,23]. It has the ability to form biofilms on both biotic (epithelial cells) and abiotic (plastic 
and glass) surfaces [24]. Bacterial biofilms are a microbial community consisting of bacterial cells 
attached to each other and to a surface, and this community is embedded in a self-produced 
extracellular matrix. The ability to form biofilm is common in nosocomial bacteria. Bacteria 
embedded within biofilms are less sensitive to antibiotics, and this leads to increased treatment costs 
and may cause fatal outcomes [20]. Consequently, the discovery of new antimicrobial agents or 
adjuvants is a major challenge for drug development and for the fight against antibiotic resistance. 
The antibacterial activity of Se-containing compounds has been described by many studies in 
the literature [25–29], and this research was mostly done by using bacteria that can cause nosocomial 
infections and/or could form biofilm, such as Escherichia coli and S. aureus. For example, a selenide 
polysaccharide showed antibacterial activity against E. coli [25], selenoesters (SeEst) exerted a potent 
action against S. aureus and Chlamydia trachomatis [26], selenazolinium salts have a potent activity 
against ESKAPE pathogens (Enterococcus, methicillin-resistant S. aureus, Klebsiella pneumoniae, 
Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter) [27], selenodiazoles have 
antimycobacterial activity [28] and 2,2′-dithyenyl diselenide showed antibacterial activity against 
Enterococcus faecalis [29]. 
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Additionally, different research groups have reported the capacity of SeNPs to inhibit or to 
hinder the formation of bacterial biofilm, mainly produced by E. coli and S. aureus [30–36]. Besides 
their aforementioned use as antiviral and antibacterial compounds, Se derivatives have also shown 
antifungal activity [29,37,38]. For example, diselenides [29], selenazoles [37] and SeNPs [38] showed 
activity against different fungal species. 
In this context, our groups have synthesized and previously described a series of 
selenoanhydrides and selenoesters that have shown very promising anticancer activity [26,39–43], as 
these derivatives can act as chemopreventive agents [39], cytostatic derivatives [39], cytotoxic 
compounds [39–42], multidrug resistance reversers [40–42] and enhancers of the activity of clinical 
chemotherapy agents such as doxorubicin and topotecan, among others [43]. More recently, these 
derivatives have also proved to be antibacterial agents against S. aureus, E. faecalis and C. trachomatis, 
with the capacity to inhibit the bacterial AcrAB-TolC efflux pump [26]. 
Given the promising biological activities of these compounds against cancer and specific 
bacterial strains, we have now explored the potential use of the selenoanhydride (SeAnh) 1 and the 
ten SeEst-containing compounds 2–11 (Figure 1) as antiviral agents against HSV-2 as antifungal 
agents and as inhibitors of bacterial biofilm formation. 
 
Figure 1. Structures of the (A) anhydrides, (B) symmetric selenodiesters and (C) selenoesters 
evaluated. 
The biofilm inhibition exerted by selenocompounds 1–11 was investigated by the microdilution 
method on Gram-positive (S. aureus ATCC 25923) and on Gram-negative bacteria (S. enterica serovar 
Typhimurium 14028s). The capacity of 1–11 to enhance the activity of antibiotics was also explored. 
To our knowledge, this is the first study describing the antibiofilm activity of synthetic 
selenocompounds, because, until now, only SeNPs have been tested against biofilms [30–36]. 
Alternatively, given these antibacterial antecedents and knowing both that selenocompounds 
can be correlated with their ability to act as pro-oxidants or as antioxidants [44,45] and that the SeAnh 
and SeEst showed chemopreventive activity in a previous study [39], we also evaluated the 
antibacterial activity of compounds 1–11 against anaerobic bacteria in oxygen-free conditions. This 
evaluation intended to ascertain whether the compounds exert their biological activities through the 
modulation of the level of ROS in their biological environments [46]. 
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2. Results 
2.1. Antiviral Activity against HSV 
Before the determination of the antiviral activity of the selenocompounds, Vero cells were 
incubated with increasing concentrations of the compounds for 24 h. The cell viability was measured 
by MTT assay and IC50 values were evaluated (Table 1), following a procedure previously described 
[47]. No significant cytotoxic action was observed following the exposure of the Vero cells to 
concentrations of the SeAnh 1 and of SeEst 2–8 up to 100 μM. In contrast, compounds 9–11 exerted 
cytotoxic properties toward Vero cells; their IC50 value was defined at 31, 45 and 39 μM, respectively. 
With the purpose of avoiding the direct toxic effects of the cytotoxic compounds, concentrations of 
the compounds at least 6-fold lower than their IC50 were used in the antiviral assay. 
Table 1. Cytotoxic activity of selenocompounds on Vero cells. 
Compounds IC50 (µM) 
1 >100 
2 >100 
3 >100 
4 >100 
5 >100 
6 >100 
7 >100 
8 >100 
9 31 
10 45 
11 39 
To determine the antiviral activity of the selenocarbonyl compounds 1–11, real-time polymerase 
chain reaction (qPCR) was performed by using Vero cells infected with HSV-2, as previously 
described [48]. The SeAnh (1) and 6 out of the SeEst (3 and 6–11) exerted potent antiviral activity 
against HSV-2. The lowest concentration which exerted antiviral activity was 12.5 μM, in the case of 
the SeAnh (1) (Figure 2A). The number of HSV-2 was significantly reduced after treatment with 
10 μM of selenocompound 3 (Figure 2B). 
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Figure 2. Antiviral activity of the selenocompounds (1, 3 and 6–11) against HSV-2, drawn as follows: 
A—compound 1, B—compound 3, C—compounds 6-8, and D—compounds 9–11. 
Moreover, the replication of HSV-2 was completely inhibited after treatment with 50 μM of 
compound 7. The lowest concentration with antiviral activity was determined at 12.5 μM, in the case 
of compound 7 and 8, while compound 6 significantly inhibited the replication of HSV-2 at 25 μM 
(Figure 2C). Compound 11 was the most potent anti-HSV-2 derivative, as it could inhibit the 
replication of HSV-2 at 1.25 μM concentration. Compound 10 also inhibited the replication of HSV-2 
at the concentration of 5 μM (Figure 2D). Treatment with compounds 2, 4 and 5, did not reduce the 
number of HSV-2 (Figure S1, Supplementary material). The lowest concentration of the reference 
compound, acyclovir, which showed antiviral activity, was 10 μM (Figure S2). In addition, acyclovir 
could not inhibit the replication of HSV-2 completely at the examined concentrations (1.25–2500 μM). 
Then, among the tested selenocompounds, 10 and 11 showed antiviral activity at 8-fold and 4-fold 
lower concentrations than acyclovir, respectively, whereas compounds 1, 3, 7 and 8 exerted antiviral 
activities at a similar concentration to acyclovir (12.5 μM). 
2.2. Antifungal Activity 
The antifungal activity of the selenocompounds 1–11 against selected pathogenic yeasts was 
determined by using the disk-diffusion method (Table 2), measuring the respective inhibition zones 
as previously described [49]. The yeast strains selected for the evaluation of the antifungal activity 
were Cryptococcus diffluens (ATCC 32059), Candida albicans (ATCC 10231), Candida krusei (ATCC 
14243), Candida tropicalis (ATCC 13803), Candida parapsilosis (ATCC 22019) and Candida glabrata 
(ATCC 36909). 
The ketone SeEst 9–11 and the cyclic SeAnh 1 showed a moderate antifungal activity on the 
tested microorganisms in the disk-diffusion assay (Table 2) and were therefore selected for 
antimicrobial susceptibility testing, using the broth microdilution assay. Compounds 6 and 8 showed 
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low antifungal activity toward C. glabrata and C. krusei, with inhibitory zones of less than 10 mm in 
diameter. In contrast, compounds 2–5 (symmetric selenodiesters) and 7 (methoxycarbonyl 
selenoester) did not show antifungal activity, as none of them generated an inhibition zone in any of 
the evaluated strains. Therefore, these compounds are not shown in Table 2, due to their lack of 
activity. 
Table 2. Screening for antifungal activity of the selenocompounds by using the disk-diffusion 
method. 
Cpd. 
Conc. on 
Disk 
Inhibition Zone Diameters (in Millimeters) in Different Fungal Strains 
Cryptococcus 
diffluens 
ATCC 32059 
Candida  
albicans 
ATCC 10231 
Candida  
tropicalis 
ATCC 13803 
Candida  
krusei ATCC 
14243 
Candida  
glabrata 
ATCC 36909 
Candida  
parapsilosis 
ATCC 22019 
1 
200 μM - 14 3 11 2 - 
10 mM - >30 >30 >30 13 6 
6 
200 μM - - - - - - 
10 mM - - - - 6 - 
8 
200 μM - - - - - - 
10 mM - - - 4 - - 
9 
200 μM 12 - 2 19 6 4 
10 mM 29 >30 25 >30 >30 >30 
10 
200 μM - - - 14 - 2 
10 mM - >30 16 >30 25 >30 
11 
200 μM 10 - - - - 14 
10 mM 18 19 - 12 18 >30 
DMSO 2 v/v% - - - - - - 
Cpd.: Compound. Conc.: Concentration. Values in bold denote inhibition-zone diameters > 10 mm. 
In the second experiment, the minimal inhibitory concentrations (MIC) of the active compounds 
(Those that showed an inhibition zone greater than 10 mm in the previous assay) were determined. 
This MIC values were calculated by using the broth microdilution method (Table 3) [50]. The MIC 
value of the active compounds was not determined for C. tropicalis or C. glabrata strains, because none 
of the four active compounds showed an inhibition zone greater than 10 mm at the 200 μM 
concentration in these two Candida fungal species. 
The MIC of the four active compounds (1 and 9–11) ranged from 50 to 100 μM (Table 3). It is 
noteworthy that the SeAnh 1 showed the lowest MIC against C. albicans (50 μM), whereas C. krusei 
was more sensitive to the ketone SeEst 9 and 10 (50 μM). The lowest MIC value found in C. diffluens 
and C. parapsilosis was 100 μM (compounds 9 and 11, respectively). 
Table 3. Minimal inhibitory concentrations (in μM) of selected Se-containing compounds and 
reference caspofungin (CSP) on susceptible fungal strains, using the broth microdilution method. 
Dates of reference are provided as a range and are calculated from the data in bibliography [51]. 
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Cryptococcus 
diffluens  
ATCC 32059 
Candida albicans  
ATCC 10231 
Candida krusei  
ATCC 14243 
Candida parapsilosis 
ATCC 22019 
1 >200 1 50 1 100 1 >200 
9 100 9 >200 9 50 9 >200 
10 >200 10 >200 10 50 10 >200 
11 100 11 >200 11 >200 11 100 
CSP ND CSP [51] ≤0.007–0.110 CSP [51] 0.055–0.229 CSP [51] 0.110–1.83 
2.3. Antibacterial Activity against Anaerobes 
The determination of the antibacterial activity against anaerobic bacteria had a dual purpose. 
The first aim of the assay was the determination of the activity of these selenocarbonyl compounds 
as antibacterials against different anaerobes, which are a group of pathogens where resistance is 
emerging steadily and for which treatment options are limited. In fact, only a few pharmacological 
agents (e.g., metronidazole, clindamycin and carbapenems) are able to exert antibacterial activity in 
anaerobic conditions [52]. The second aim was to test the activity of compounds 1–11 in anaerobic 
conditions, in order to determine if their mechanism of action depends on the presence of oxygen, 
because the literature suggests that the organoselenium compounds exert their biological activities 
through the modulation of the level of ROS in biological environments [46]. The antibacterial activity 
of the compounds was assessed in three anaerobic species: Clostridium perfringens ATCC 13124, 
Bacteroides fragilis ATCC 25285 and Propionibacterium acnes ATCC 11827. The standard disk-diffusion 
method was employed to determine the inhibition zones of the compounds [53]. A compound was 
considered inactive when the diameter of the inhibition zones was smaller than 10 mm in the two 
concentrations tested (200 and 10 mM). 
The selenocompounds (1–11) did not inhibit the growth of anaerobic Gram-positive or Gram-
negative bacteria at the two tested concentrations, as the diameter of the inhibition zones was always 
smaller than 10 mm. 
2.4. Antibiofilm Activity against S. Aureus and S. Typhimurium 
The antibacterial activity against S. Typhimurium exerted by the selenocompounds (1–11) was 
assessed. The antibacterial effect of these derivatives against S. aureus ATCC was determined 
previously [26]. Only compounds 9 (MIC: 3.12 μM) and 10 (MIC: 25 μM) had an antibacterial effect 
(MIC: 100 μM or > 100 μM, respectively) on S. aureus ATCC 25923. According to the bibliography, 
ciprofloxacin has an MIC of 0.125 μg/mL (0.377 μM) against S. Typhimurium [54]. 
The antibiofilm effect of selenocompounds on S. aureus and S. Typhimurium was evaluated. 
Selenocompounds 1, 6–8 and 10–11 significantly inhibited (>70%) the biofilm formation of S. aureus. 
Compounds 1 and 6–8 were the most effective at 50 μM, whereas the ketone-containing SeEst 10 at 
10 μM and 11 at 25 μM were effective against S. aureus biofilm (Figure 3A). Except for compounds 6 
and 11, all derivatives showed significant (>45% or higher) biofilm inhibition at 50 μM on 
S. Typhimurium. The most potent selenocompounds with antibiofilm effect were 4 and 5 at 50 μM, 
showing 75% and 73% of inhibition, respectively (Figure 3B). 
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Figure 3. Antibiofilm effect of selenocompounds on S. aureus ATCC 25923 (A) at 50 μM (the following 
compounds were applied in different concentrations: 9 at 1 μM, 10 at 10 μM and 11 at 25 μM) and S. 
enterica serovar Typhimurium 14028s (B) at 50 μM. 
2.5. Antibiofilm Activity against S. Aureus and S. Typhimurium in Combination with Antibiotics 
The combination effect between the antibiofilm compounds and ciprofloxacin (CIP) against S. 
aureus was assessed and the combined activity with tetracycline (TET) was evaluated on S. 
Typhimurium, selecting in each separate experiment the five most active compounds (1, 7, 8, 10 and 
11 for S. aureus; 4, 5, 7, 8 and 9 for S. Typhimurium). 
Most of the compounds at a 50 μM concentration reduced the antibiofilm effect of CIP against 
S. aureus at the concentrations of 0.4, 0.8 and 1.6 μM. The exceptions were compounds 7 and 11, which 
significantly increased the activity of CIP at 1.6 μM on S. aureus ATCC 25923 (Figure 4). No significant 
variations over the antibiofilm effect were exerted by CIP at a concentration of 3.2 μM. 
 
Figure 4. Antibiofilm effect of ciprofloxacin and selenocompounds (½ MIC; columns: compounds 1, 
7, 8, 10 and 11) on S. aureus ATCC 25923. 
Compounds 4, 8 and 9 showed significantly higher antibiofilm effects in the presence of 1.25 μM 
of TET; furthermore, compounds 5, 7, 8 and 9 in the presence of 2.5 μM of TET significantly reduced 
the activity of the antibiotic compared to TET alone against S. Typhimurium (Figure 5). No significant 
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variations of the activity of TET were observed when TET was administered at concentrations of 5 or 
10 μM. 
 
Figure 5. Antibiofilm effect of tetracycline and selenocompounds (½ MIC; columns: compounds 4, 5, 
7, 8 and 9) on S. enterica serovar Typhimurium 14028s. 
3. Discussion 
3.1. Antiviral Activity against HSV 
As commented in section 2.1, the selenocompounds evaluated herein showed a potent action 
against HSV-2, with SeEst 11 having the most potent antiviral activity at concentration of 1.25 μM. 
SeAnh (1) and SeEst (3 and 6–10) were also promising anti-HSV-2 compounds. All of them exerted a 
selective action against HSV-2: compounds 1, 6, 7, 8, 10 and 11 showed a significant antiviral activity 
at concentrations of 12.5, 50, 12.5, 12.5, 5 and 1.25 μM, respectively, whereas their IC50 values in Vero 
cells were at higher concentrations: 100, 100, 100, 100, 45 and 39 μM, respectively. This means that 
antiviral activity is observed at concentrations 8-, 2-, 8-, 8-, 9- and 31-fold lower, respectively, than 
the ones at which cytotoxic effects are observed in the host cells. 
The high selectivity of the compounds can be explained by the fact that these derivatives 
generate ROS. In normal cells with an adequate ROS level, a ROS-generating drug increases the ROS 
levels, but without reaching the critical threshold at which cells triggers the apoptotic or necrotic 
processes. Nevertheless, in a cancer or an infected cell (like the case of the Vero cells infected by the 
HSV-2), the ROS balance is shifted toward this threshold, and the additional ROS released by the 
action of the ROS-generating drug can exceed the limit, causing the death of the cell, as described by 
Jamier et al. [55]. In line with these activity observations in antiviral assays, the SeAnh 1 and the 
ketone-containing SeEst 9–11 are pro-apoptotic compounds, as reported previously [40,41]. 
Interestingly, SeAnh 1 is a reactive compound that can be hydrolyzed easily [39], releasing ionic 
species of Se that can then exert their pro-oxidant action. The SeEst, although also capable of being 
hydrolyzed, are less reactive, as the hydrolysable group is protected inside the structure of the 
molecule, and thus these compounds are not such strong pro-oxidants like 1. 
Interestingly, some structure activity relationships can be extracted, but with the caveat that this 
is based on a small number of compounds. Among the SeEst, ketone derivatives 10 and 11 are potent 
and selective antiviral compounds that exert their antiviral action against HSV-2 at concentrations in 
the low micromolar range. When this ketone is replaced by a methyl oxygen ester or by an amide, 
the detected antiviral activity is lower, as the effect is observed if the concentrations are in the range 
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of 12.5 to 50 μM. Finally, selenodiesters 2–5 did not show relevant antiviral activity in the 
concentrations assayed. 
3.2. Antifungal Activity 
Although only four compounds exerted a moderate antifungal activity, the results show an 
interesting pattern of selectivity, since some of the tested compounds were effective against C. krusei 
and C. parapsilosis. Both organisms have attributes that make the administration of the appropriate 
antifungal therapy problematic, because C. krusei is not susceptible to fluconazole and C. parapsilosis 
has reduced susceptibility to the echinocandins. These drugs are important agents in the treatment 
of systemic fungemia, and both C. krusei and C. parapsilosis are multidrug resistant opportunistic 
fungal pathogens [56]. In the foreseeable future, the treatment of resistant non-albicans Candida (NAC) 
will present serious issues for clinicians; therefore, the importance of research in this area should be 
highlighted. In spite of the modest activity found, these results are of particular interest, since 
optimization of this preliminary activity of the most active Se derivatives could lead to novel 
antifungal selenocompounds active at low micromolar concentration range. 
3.3. Antibacterial Activity against Anaerobes 
The lack of activity of the selenocompounds 1–11 in an anaerobic atmosphere suggests that the 
ROS-modulation activity of these compounds requires the presence of oxygen to trigger the cellular 
processes that are ultimately responsible for their antibacterial activity. 
A second possible explanation of these results is that the compounds may not be able to get 
inside bacterial cells in anaerobic conditions, as has been described for aminoglycosides [57]. 
The lack of activity of these selenocarbonyl compounds against anaerobes suggests that their 
capacity to act as antioxidants is related to the formation or the scavenging of ROS in aerobic media 
[39,44,45]. This fact is interesting, as it improves the knowledge of the mechanism of action of the 
compounds and highlights the ambivalence of Se in the ROS modulation, frequently observed in the 
evaluated selenocompounds with anticancer activity. On one hand, Se is crucial to the removal of the 
free radicals in cellular media, through its incorporation in the form of selenocysteine to the different 
glutathione peroxidases. On the other hand, certain Se-containing derivatives can generate ROS and 
these ROS can then trigger apoptotic processes, induce mutations, or generate DNA breaks, among 
other effects [39,41,44,45]. 
3.4. Antibiofilm Activity against S. aureus and S. Typhimurium 
Obtained results indicated that the SeAnh 1 and the SeEst containing a carbonyl group in the 
alkyl moiety bound to the Se atom (6–8, 10 and 11) showed a more potent antibiofilm activity against 
the Gram-positive S. aureus than the exerted by the dimethyl selenodiesters 2–5, showing the 
relevance of this –COSeCH2CO– moiety for the antibiofilm activity. Furthermore, compounds 10 and 
11 exerted this antibiofilm activity against S. aureus at a lower concentration (10 and 25 μM, 
respectively). 
Interestingly, the dimethyl selenodiesters 4 and 5, which contain a phenyl ring, were the most 
potent inhibitors of the biofilm formation in the Gram-negative S. Typhimurium at a 50 μM 
concentration, indicating the promising potential of these two difunctionalized derivatives against 
the assayed Gram-negative species. The derivatives 7–10 (with a –COSeCH2CO– moiety) and the 
dimethyl heteroarylselenodiesters 2 and 3 also exerted a biofilm inhibiting activity higher than 50% 
in S. Typhimurium. The observation that the changes in the compounds’ structure are able to 
modulate the antibiofilm activity is very interesting and suggests that we may be able to improve the 
activity further and ascertain the structure relationships behind this differential action. This fact 
would enable the potential discovery of more-potent antibiofilm inhibitors against S. Typhimurium 
and against S. aureus. 
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3.5. Antibiofilm Activity against S. aureus and S. Typhimurium in Combination with Antibiotics 
The results showed that the synergistic antibiofilm effect of the compounds in combination with 
antibiotics was dependent on the concentration of antibacterial agents. However, the compounds 
interact in an antagonistic or in a neutral manner with the selected antibiotics and strains 
(ciprofloxacin and S. aureus, tetracycline and S. Typhimurium). Against S. aureus, the exceptions to 
this general trend were compounds 7 and 11 together with a 1.6 μM concentration of CIP. 
Furthermore, against S. Typhimurium, the exceptions were compounds 4, 8 and 9, in combination 
with a 1.25 μM concentration of TET. 
The results indicate that combining these compounds with antibiotics may require a careful 
testing of specific combinations. As these derivatives showed an intrinsic antibiofilm activity, they 
could be used to coat surfaces for medical prostheses, like the different SeNPs discussed in the 
introduction, with potential applications in the reduction of the adherence of E. coli and S. aureus to 
surfaces, as well as in the inhibition of biofilm formation [30,36]. 
4. Materials and Methods 
4.1. Chemistry 
The cyclic SeAnh (1) and the ten SeEst investigated in this study (2–11) were synthesized by the 
group of Prof. Dr. Juan Antonio Palop, Prof. Dr. Carmen Sanmartín and Dr. Enrique Domínguez-
Álvarez at the University of Navarra (Pamplona, Spain). Their synthesis and characterization were 
described in a previous work [39]. A resynthesis of the compounds was carried out, to obtain the 
amount necessary for performing the biological assays described in this work. The compounds purity 
and their structure were confirmed by using standard techniques in the characterization of organic 
compounds (elemental analysis, MS, IR, 1H-NMR and 13C-NMR), as previously described [39]. 
The chemicals used in this study during the determination of the biological activities were 
sodium dodecyl sulfate (SDS; Sigma, St Louis, MO, USA), 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT; Sigma, St Louis, MO, USA) and DMSO (dimethyl sulfoxide; 
Sigma). Stock solutions of the tested compounds (Figure 1) were prepared in DMSO, and the working 
solutions were prepared by subsequent dilutions of DMSO stock solutions in water. None of the 
assayed solutions in biological experiments had a concentration >1% of DMSO, and all solutions were 
prepared and used the day of the assay. 
4.2. Strains and Cell Lines Used 
4.2.1. Viral Strains 
Herpes simplex virus-2 (HSV-2) was kindly provided by Dr. Ilona Mucsi (Department of 
Medical Microbiology and Immunobiology, University of Szeged) for its use in the antiviral assay. 
The titer of the HSV-2 was determined by plaque titration method and expressed in plaque-forming 
units (PFU)/mL. 
4.2.2. Cell Lines 
Vero (African green monkey kidney) cells (ATCC CRL-1586) were purchased from LGC 
Promochem, Teddington, UK. The cells were cultured in Eagle’s Minimum Essential Medium 
(EMEM) supplemented with 10% heat-inactivated fetal bovine serum (Sigma-Aldrich, St Louis, MO, 
USA), 4 mM of L-glutamine (Sigma-Aldrich, St Louis, MO, USA), 1 mM of Na-pyruvate, a selection 
of non-essential amino acids (NEAA) and with a penicillin-streptomycin (Sigma-Aldrich, St Louis, 
MO, USA) mixture in concentrations of 100 U/L and 10 mg/L, respectively. Vero cells were used in 
the antiviral assay. 
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4.2.3. Fungal Strains 
Candida albicans ATCC 10231, C. tropicalis ATCC 13803, C. krusei ATCC 14243, C. glabrata ATCC 
36909, C. parapsilosis ATCC 22109 and Cryptococcus diffluens ATCC 32059 were used as test organisms 
in the antifungal activity assays. 
4.2.4. Bacterial Strains 
Bacteroides fragilis ATCC 25285 (Gram-negative; strict-anaerobe), Clostridium perfringens ATCC 
13124 (Gram-positive; strict anaerobe) and Propionibacterium acnes ATCC 11827 (Gram-positive; 
aerotolerant anaerobe) were used in the antimicrobial susceptibility assay of anaerobic bacteria to the 
selenocompounds studied herein. 
The Gram-negative biofilm forming Salmonella enterica serovar Typhimurium 14028s was used 
in the biofilm formation assay. The Gram-positive Staphylococcus aureus strain ATCC 25923 was 
purchased from ATCC and used in the biofilm formation assay. 
4.3. Assay for Anti-HSV-2 Activity 
The MTT assay was performed to quantify the cytotoxic activity of the tested compounds on 
Vero cells, as described previously [47]. A starting concentration of 100 μM of the selenocompounds 
was used, and optical density was used to determine the cell growth. Inhibitory concentration 50 
(IC50) was calculated as the concentration at which the compounds were able to diminish Vero cells’ 
growth by 50%. With the aim of evaluating the anti-HSV-2 activity of the selenocompounds, Vero 
cells were seeded into 96-well plates and were infected with HSV-2 at a multiplicity of infection (MOI) 
of 0.01 and treated with the compounds in two-fold dilutions for 1 h at 37 °C. The starting 
concentrations of the compounds were chosen in accordance with their cytotoxicity on Vero cells. 
Control cultures were incubated with media without compounds. Acyclovir were used as reference 
compound, at an initial concentration of 2.5 mM. After a 24 h incubation period, the cultures were 
washed with phosphate buffered saline. Then, 100 μL of Milli-Q water (MQ) (Millipore, Billerica, 
MA, USA) was added to the cells, and the cultures in the plate were frozen. To determine the number 
of HSV-2, qPCR assay was performed, as previously described [48,58,59]. The qPCR mixture 
consisted of 5 μL of SsoFast™ EvaGreen® Supermix (Bio-Rad, Hercules, CA, USA), 1–1 μL of forward 
and reverse primers (10 pmol/μL each), and 1 μL of template; in addition, 2 μL of MQ water was 
added to get a final volume of 10 μL. The virus inhibitory effect was evaluated by comparing virus 
titers obtained in the presence and absence of compounds. 
4.4. Antifungal Activity against Pathogenic Yeasts 
Disk diffusion. The antifungal activity of the selenocompounds against selected pathogenic yeasts 
were screened, measuring their inhibition zones [49]. Solutions of the selenocompounds were set at 
two concentrations: 200 μM (from a 10 mM stock solution) and 10 mM. The sterile filter paper discs 
(diameter (D) 6 mm) impregnated with the solutions (10 μL of solutions) were placed on Saboraud 
Dextrose Agar (SDA), inoculated with the respective suspensions of yeasts (inocula of 0.5 
McFarland’s standard). The solvent (DMSO) served as negative control, and an additional plate was 
inoculated without disks, to serve as growth control. The inocula were used within 15 min of 
preparation, the disks were applied within 15 min of inoculating the plates, and incubation started 
within 15 min of application of the disks (according to EUCAST standards). The plates were then 
incubated for 72 h, under aerobic conditions, at 37 °C. Inhibition zone diameters generated by the 
tested compounds (including the diameter of the disc) were measured. All experiments were 
performed in triplicate. 
Broth microdilution method. The compounds that showed activity in the disk-diffusion assay were 
further subjected to the determination of their minimum inhibitory concentrations on the relevant 
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fungal strains. Determination of the MIC values was performed by using the broth microdilution 
method, according to EUCAST standards [50]. 
4.5. Antibacterial Activity against Anaerobic Bacteria 
The antibacterial activity of the selenocompounds against the selected anaerobic bacterial strains 
was assessed by measuring their inhibition zones by standard disk-diffusion method [53]. Solutions 
of the selenocompounds were set at two concentrations: 200 μM (from a 10 mM stock solution) and 
10 mM. The sterile filter paper discs (D = 6 mm) impregnated with the solutions (10 μl of solutions) 
were placed on Schaedler agar plates (SCS; bioMérieux), inoculated with the respective bacterial 
suspensions (inocula of 0.5 McFarland’s standard). The solvent (DMSO) served as negative control, 
and an additional plate was inoculated without disks as bacterial growth control. The inocula were 
used within 15 min of preparation, the disks were applied within 15 min of inoculating the plates, 
and incubation started within 15 min of application of the disks (according to EUCAST standards) 
[53]. The plates were then incubated for 72 h, under anaerobic conditions, in an anaerobic chamber 
(Baker Ruskinn anaerobic workstation). Inhibition-zone diameters generated by the tested 
compounds (including the diameter of the disc) were measured. All experiments were performed in 
triplicate. 
4.6. Measuring Biofilm Formation Using Crystal Violet 
The biofilm-forming ability of S. Typhimurium and S. aureus ATCC strains was studied in 
96-well microtiter plates, using Luria-Bertani (LB) broth without salt (S. Typhimurium) or tryptic soy 
broth TSB (S. aureus) in the presence of selenocompounds. Initially, overnight cultures were diluted 
to an optical density (OD) of 0.1 at 600 nm and then added to each well, with the exception of the 
medium control wells and compounds were added individually at ½ MIC. The final volume was 200 
μL in each well. Plates were incubated at 30 °C, for 48 h, with gentle agitation (100 rpm). After the 
incubation period, the medium was discarded, and the plate was washed with tap water, to remove 
unattached cells. Then, 200 μL of crystal violet (CV; 0.1% [v/v]) was added to the wells and incubated 
for 15 min at room temperature. CV was removed from the wells, and the plate was washed again 
with tap water. Then, 200 μL of 70% ethanol was added to each well, and the biofilm formation was 
determined by measuring the OD at 600 nm, using a FLUOstar Optima plate reader (BMG Labtech, 
Aylesbury, UK). The antibiofilm effect of selenocompounds was expressed in the percentage (%) 
decrease in biofilm formation. The assay was repeated a minimum of three times. The results were 
analyzed by using the t-test and p-values of <0.05 were considered significant. 
4.7. Enhancement of the Activity of Antibiotics against Biofilm Formation 
The chemosensitization exerted by the tested selenocompounds against biofilm formation was 
evaluated with antibiotics (TET or CIP) in the presence of non-inhibitory concentrations of the 
compounds (½ MIC) in both S. Typhimurium and S. aureus strains. The effect was determined by 
two-fold broth microdilution method in 96-well plates, using serial dilutions of TET and CIP. The 
first four rows contained two-fold dilutions of antibiotics, and combinations of the antibiotics and 
tested compounds were added into the last four rows. The overnight bacterial cultures were diluted 
to an OD of 0.1 at 600 nm and then added to each well, in 50 μL LB, without salt or TSB, with the 
exception of the medium control wells. The plates were then incubated at 30 °C, for 48 h, with gentle 
agitation (100 rpm), and the biofilm formation was determined by measuring the OD at 600 nm, using 
a FLUOstar Optima plate reader. The antibiofilm effect of antibiotic alone and in combination with 
selenocompounds was expressed in the percentage (%) of decrease in biofilm formation. The results 
were analyzed by using the t-test and p-values of <0.05 were considered significant. 
4.8. Statistical Analysis 
All values are given as the mean ± standard deviation determined for three replicates from three 
independent experiments. The statistical analysis of the data was performed with SigmaPlot for 
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Windows Version 12.0 software (Systat Software Inc, San Jose, CA, USA), using the two-tailed t-test 
for independent samples. Differences were considered statistically significant when p < 0.05. 
5. Conclusions 
To conclude, the antiviral, antifungal, antibiofilm and antibacterial (against anaerobes) activities 
of a selenoanhydride and of selected selenoesters were evaluated, taking into account that these 
derivatives have shown promising anticancer, chemopreventive and multidrug resistance reversing 
activities in previous works. Regarding the anti-HSV activity, selenoesters 3, 6–11 and the 
selenoanhydride 1 have shown a promising antiviral activity against HSV-2. These results are very 
promising and after the appropriate optimization of the structure of the active compounds, future 
experiments could lead to the development of very potent and selective novel antiviral agents. 
Alternatively, results suggested that selenocompounds could be effective adjuvants in the 
treatment of infections caused by biofilm-producing strains of S. aureus and of S. Typhimurium: 
selenocompounds 1 and 6–8 at 50 μM, and 10 and 11 at lower concentrations were the most potent 
agents on S. aureus, whereas compounds 7 and 11 at 50 μM significantly enhanced the antibiofilm 
effect of CIP. On the other hand, in S. Typhimurium compounds 4 and 5 significantly decreased the 
biofilm mass, and compounds 4, 8 and 9 exerted synergistic effect against S. Typhimurium in 
combination with TET at 1.25 μM. This activity is noteworthy and is in line with previous work that 
highlights the antibacterial activity of these compounds against S. aureus and C. trachomatis. 
Regarding the antifungal activity, the selenoanhydride 1 and the oxoselenoesters 9–11 exerted a 
moderate antifungal activity against resistant strains of Candida spp., such as C. krusei and C. 
parapsilosis. Finally, the evaluated compounds were inactive against anaerobic bacteria, suggesting 
that the mechanism of action responsible for their activity requires the presence of oxygen. 
Concerning the structure-activity relationships, it has been confirmed in this study that the 
phthalic SeAnh 1 and the oxoselenoesters 9–11 are appealing structures, with potent antiviral activity, 
noteworthy antibiofilm activity, and moderate antifungal activity, in accordance with previous 
investigations that determined the multidrug resistance reversing and chemopreventive, 
furthermore pro-apoptotic activity in cancer models in vitro. 
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